Payment overview · 2025
General Payments
$13,170.11
137 reported records · 34 companies
Healthcare provider profile · identity verified
Michael Sokol, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism · OVERLAND PARK, KS · NPI 1235163676
Verified facts
What the public records show
CMS Open Payments records show Michael Sokol, MD received $13,170.11 in general payments during 2025 across 137 reported records.
Abbott Laboratories accounted for 77.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 59 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Afrezza, Farxiga, Jardiance, Kerendia, Mounjaro, Ozempic, Rybelsus, Synthroid, Unithroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 214 claims for Synthroid by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UNITHROID as an associated drug or biological on 7282 records involving 3230 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Unithroid by this doctor in 2024.
Antares Pharma, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TLANDO as an associated drug or biological on 80 records involving 68 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Tlando by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Synjardy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 258 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 174 claims for Trulicity by this doctor in 2024.
Mannkind Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AFREZZA as an associated drug or biological on 10645 records involving 3625 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Afrezza by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 574 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GENOTROPIN as an associated drug or biological on 864 records involving 515 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Genotropin by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $10,187.04 | 77.3% | 22 | 2025 |
| Chiesi USA, Inc. | Unresolved — no canonical attribution shown | $625.00 | 4.8% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $380.62 | 2.9% | 16 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $220.19 | 1.7% | 20 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $199.43 | 1.5% | 13 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $154.63 | 1.2% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $152.03 | 1.1% | 8 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $142.80 | 1.1% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $110.25 | 0.8% | 4 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $100.35 | 0.8% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $100.28 | 0.8% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $97.25 | 0.7% | 6 | 2025 |
| PROTEGA PHARMACEUTIALS INC | Unresolved — no canonical attribution shown | $67.29 | 0.5% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $64.42 | 0.5% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $55.25 | 0.4% | 3 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $54.73 | 0.4% | 2 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $44.67 | 0.3% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.17 | 0.2% | 2 | 2025 |
| BETA BIONICS, INC. | Unresolved — no canonical attribution shown | $32.85 | 0.2% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $32.03 | 0.2% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $31.45 | 0.2% | 2 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $29.84 | 0.2% | 1 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $28.99 | 0.2% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $26.83 | 0.2% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $26.17 | 0.2% | 1 | 2025 |
| Ascendis Pharma Endocrinology Inc | Unresolved — no canonical attribution shown | $24.61 | 0.2% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $22.17 | 0.2% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $21.81 | 0.2% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $20.14 | 0.1% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $18.44 | 0.1% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $18.02 | 0.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.01 | 0.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.53 | 0.1% | 1 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $13.82 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $7,675.00 | 2 |
| Food and Beverage | $2,888.48 | 126 |
| Compensation for serving as faculty or as a speaker for a medical education program | $1,250.00 | 2 |
| Travel and Lodging | $689.13 | 4 |
| Honoraria | $625.00 | 2 |
| Education | $42.50 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $10,187.04 | 22 | 2025 |
Source payment records
|
|||||
| MYCAPSSA Normalized: mycapssa |
Drug | Chiesi USA, Inc. | $325.00 | 1 | 2025 |
Source payment records
|
|||||
| MYALEPT Normalized: myalept |
Drug | Chiesi USA, Inc. | $300.00 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $204.82 | 2 | 2025 |
Source payment records
|
|||||
| CRENESSITY Normalized: crenessity |
Drug | Neurocrine BioSciences, Inc. | $154.63 | 3 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $142.80 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $110.25 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $107.00 | 11 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $105.14 | 7 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $100.63 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $100.63 | 5 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $100.35 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $82.24 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $80.07 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $78.68 | 7 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $78.68 | 7 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $69.01 | 4 | 2025 |
Source payment records
|
|||||
| ROXYBOND Normalized: roxybond |
Drug | PROTEGA PHARMACEUTIALS INC | $67.29 | 3 | 2025 |
Source payment records
|
|||||
| SOMAVERT Normalized: somavert |
Drug | PFIZER INC. | $66.25 | 6 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $64.42 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $57.66 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $55.25 | 3 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $54.73 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $51.98 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $50.32 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $46.94 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $46.94 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $46.94 | 3 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $44.70 | 3 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $44.67 | 2 | 2025 |
Source payment records
|
|||||
| Sogroya Normalized: sogroya |
Biological | Novo Nordisk Inc | $42.43 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $37.99 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $36.29 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $34.25 | 2 | 2025 |
Source payment records
|
|||||
| iLet Bionic Pancreas Normalized: ilet bionic pancreas |
Device | BETA BIONICS, INC. | $32.85 | 1 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Contact Detach Normalized: ilet insulin infusion kit contact detach |
Device | BETA BIONICS, INC. | $32.85 | 1 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Inset Normalized: ilet insulin infusion kit inset |
Device | BETA BIONICS, INC. | $32.85 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $32.03 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $31.45 | 2 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $31.42 | 2 | 2025 |
Source payment records
|
|||||
| ISTURISA Normalized: isturisa |
Drug | RECORDATI_RARE_DISEASES_INC. | $29.84 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $29.49 | 2 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $28.99 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $26.83 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $26.17 | 1 | 2025 |
Source payment records
|
|||||
| Yorvipath Normalized: yorvipath |
Drug | Ascendis Pharma Endocrinology Inc | $24.61 | 1 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $22.17 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $21.81 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.83 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $20.14 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $18.44 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $18.44 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $18.44 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $18.02 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $18.01 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.78 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.53 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.53 | 1 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $13.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AFREZZA afrezza |
2025 | Afrezza | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 143 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 134 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 258 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 574 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 62 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 214 | exact normalized | Medicare Part D |
| UNITHROID unithroid |
2025 | Unithroid | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
214 | 53 |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | UNITHROID open payments reported associated product |
CMS Open Payments — General Payments 7282 supporting records · 3230 recipient NPIs · example record 1220525525 |
Unithroid · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Antares Pharma, Inc. Exact reporting entity; no affiliate inference |
2025 | TLANDO open payments reported associated product |
CMS Open Payments — General Payments 80 supporting records · 68 recipient NPIs · example record 1235880990 |
Tlando · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
143 | 37 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
134 | 37 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
67 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
134 | 37 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
258 | 55 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
174 | 49 |
| Mannkind Corporation Exact reporting entity; no affiliate inference |
2025 | AFREZZA open payments reported associated product |
CMS Open Payments — General Payments 10645 supporting records · 3625 recipient NPIs · example record 1250869202 |
Afrezza · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
574 | 123 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
62 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | GENOTROPIN open payments reported associated product |
CMS Open Payments — General Payments 864 supporting records · 515 recipient NPIs · example record 1228794127 |
Genotropin · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 621 | 170 |
| Ozempic | Semaglutide | 574 | 123 |
| Pioglitazone Hcl | Pioglitazone Hcl | 365 | 110 |
| Mounjaro | Tirzepatide | 258 | 55 |
| Metformin Hcl | Metformin Hcl | 249 | 75 |
| Tresiba Flextouch U-100 | Insulin Degludec | 229 | 66 |
| Atorvastatin Calcium | Atorvastatin Calcium | 226 | 70 |
| Synthroid | Levothyroxine Sodium | 214 | 53 |
| Metformin Hcl Er | Metformin Hcl | 184 | 57 |
| Glimepiride | Glimepiride | 177 | 50 |
| Trulicity | Dulaglutide | 174 | 49 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 150 | 49 |
| Farxiga | Dapagliflozin Propanediol | 143 | 37 |
| Jardiance | Empagliflozin | 134 | 37 |
| Losartan Potassium | Losartan Potassium | 104 | 39 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 96 | 41 |
| Simvastatin | Simvastatin | 85 | 25 |
| Lisinopril | Lisinopril | 81 | 20 |
| Alendronate Sodium | Alendronate Sodium | 79 | 24 |
| Humalog Kwikpen U-100 | Insulin Lispro | 79 | 26 |
| Ezetimibe | Ezetimibe | 77 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 73 | 27 |
| Carvedilol | Carvedilol | 71 | 23 |
| Synjardy | Empagliflozin/Metformin Hcl | 67 | 17 |
| Novolog Flexpen | Insulin Aspart | 66 | 25 |
| Rybelsus | Semaglutide | 62 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 60 | 18 |
| Allopurinol | Allopurinol | 57 | 18 |
| Gabapentin | Gabapentin | 54 | 19 |
| Hydrocortisone | Hydrocortisone | 53 | 13 |
| Trazodone Hcl | Trazodone Hcl | 53 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 49 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 49 | 16 |
| Amlodipine Besylate | Amlodipine Besylate | 48 | 22 |
| Methimazole | Methimazole | 47 | 12 |
| Bydureon Bcise | Exenatide Microspheres | 46 | 13 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 46 | 14 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 45 | 12 |
| Januvia | Sitagliptin Phosphate | 44 | 16 |
| Levemir Flexpen | Insulin Detemir | 42 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 41 | 13 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | 12 |
| Vascepa | Icosapent Ethyl | 38 | suppressed |
| Novolog | Insulin Aspart | 37 | 12 |
| Humalog | Insulin Lispro | 35 | suppressed |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 35 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 34 | 11 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 34 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 32 | 14 |
| Invokana | Canagliflozin | 32 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 32 | 11 |
| Furosemide | Furosemide | 30 | 11 |
| Irbesartan | Irbesartan | 30 | suppressed |
| Alprazolam | Alprazolam | 29 | 15 |
| Genotropin | Somatropin | 29 | suppressed |
| Testosterone | Testosterone | 29 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 28 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 28 | 11 |
| Montelukast Sodium | Montelukast Sodium | 28 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 27 | 12 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | 11 |
| Dexamethasone | Dexamethasone | 26 | 14 |
| Spironolactone | Spironolactone | 26 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 25 | suppressed |
| Indapamide | Indapamide | 24 | suppressed |
| Tlando | Testosterone Undecanoate | 24 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Omeprazole | Omeprazole | 23 | suppressed |
| Potassium Chloride | Potassium Chloride | 22 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 22 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Calcitriol | Calcitriol | 21 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 21 | suppressed |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Unithroid | Levothyroxine Sodium | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 19 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 18 | suppressed |
| Kerendia | Finerenone | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Clonazepam | Clonazepam | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 15 | suppressed |
| Cabergoline | Cabergoline | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 14 | suppressed |
| Afrezza | Insulin Regular, Human | 13 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 13 | suppressed |
| Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 13 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Meloxicam | Meloxicam | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Gvoke Hypopen 2-Pack | Glucagon | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 12 | suppressed |
| Metyrosine | Metyrosine | 12 | suppressed |
| Tolvaptan | Tolvaptan | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $13,170.11 · 137 records | Abbott Laboratories | ABRYSVO, AFREZZA, AIRSUPRA, AREXVY, BREZTRI, CAPLYTA, COMIRNATY, CRENESSITY, CRYSVITA, ELIQUIS, EVENITY, FARXIGA, FREESTYLE LIBRE 3, Flector, GEMTESA, GVOKE HYPOPEN, INJECTAFER, ISTURISA, JARDIANCE, KISUNLA, Kerendia, Korlym, Licart, MOUNJARO, MYALEPT, MYCAPSSA, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, PROLIA, QULIPTA, REPATHA, REZDIFFRA, ROXYBOND, Rybelsus, SHINGRIX, SMARTVEST, SOMAVERT, SYNTHROID, Sogroya, TEPEZZA, Tirosint, Tymlos, UBRELVY, UNITHROID, VRAYLAR, Veozah, WATCHMAN FLX, XYOSTED, Yorvipath, ZAVZPRET, ZENPEP, ZEPBOUND, iLet Bionic Pancreas, iLet Insulin Infusion Kit Contact Detach, iLet Insulin Infusion Kit Inset, t:slim X2 Insulin Pump with Control-IQ | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Afrezza play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error